• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec30
Ultragenyx Completes Rolling Submission of BLA for DTX401 Gene Therapy
21:12
Dec29
William Blair Analyst Maintains Buy Rating on Ultragenyx
16:42
Ultragenyx Announces Setriusumab Phase 3 Trial Misses Main Endpoint
13:30
Dec11
Ultragenyx CFO Reports Sale of Company Shares
17:12
Nov16
Ultragenyx Secures $400 Million Non-Dilutive Financing and Expands Crysvita Royalties
22:02
Nov5
Morgan Stanley Reiterates Buy Rating on Ultragenyx Pharmaceutical
17:21

Schedules & Filings

Schedules
Filings
Nov4
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 159.93 M, Net Income -180.41 M, EPS -1.8082

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 166.5 M, Net Income -114.95 M, EPS -1.1674

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 139.29 M, Net Income -151.08 M, EPS -1.569

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
EKSO
10.580
+93.77%
+5.120
AEHL
2.180
+92.92%
+1.050
AFJK
82.580
+89.19%
+38.930
PFSA
0.1218
+78.33%
+0.053
DLXY
1.410
+67.86%
+0.570
ULY
2.760
+52.49%
+0.950
MENS
4.220
+51.80%
+1.440
CETX
2.980
+41.23%
+0.870
DAIC
0.5500
+39.06%
+0.154
ONTF
8.060
+37.54%
+2.200
View More